Case Report: Severe cutaneous adverse event associated with checkpoint inhibition in the setting of CAR T-cell therapy: beyond CRS

RT @FrontOncology: New research: Case Report: Severe cutaneous adverse event associated with checkpoint inhibition in the setting of CAR T-…

New research: Case Report: Severe cutaneous adverse event associated with checkpoint inhibition in the setting of CAR T-cell therapy: beyond CRS: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy actually represents the standard of care… #oncology h